Work

Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease: reply

Year: 2017
Type: letter
Abstract: Sir, We appreciated reading the letter of Piga et al. [1] in response to our recent report concerning the detection of autoantibodies directed to anti-dsDNA in SLE [2]. In this letter, they discuss their own results of serial measurements of anti-dsDNA using RIA by the Farr assay [3]. Comparable findings were obtained regarding the number of patients who had an increased anti-dsDNA >20% level in the 6 months prior to flare occurrence. Moreover, they demonstrated that intensification in immunosuppressive treatment could be effective in preventing flares in patients who experienced an increase in anti-dsDNA level ⩾50% without any symptoms (n = 64), as none of the patients who were treated (n = 15) had a flare, but 32.6% (16/49) of the non-treated patients did experienced a flare. So both our studies confirm the fact that monitoring anti-dsDNA levels is important in the follow-up of SLE patients. Their main concern is that by using enzyme-labelled anti-isotype assay (EliA), which has a high specificity but a lower sensitivity in quiescent SLE, early changes in anti-dsDNA levels are missed. However, when comparing EliA and the Farr assay, as we did in our study, the same percentages of patients with an increase of anti-dsDNA before an exacerbation were found. Also when we apply this at ⩾50% threshold instead of a ⩾20% increase, only two patients would have been missed using EliA, but also by using Farr. So, even though EliA is less sensitive in quiescent disease, an increase in anti-dsDNA levels probably will be detected by using this technique. As Piga et al. stated, a relative increase is much more important than absolute values, as steadily increased anti-dsDNA do not predict a flare. Of course, prospective studies using EliA should be performed to confirm these findings. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: The authors have declared no conflicts of interest.
Source: Rheumatology
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,597
OpenAlex ID: W2744229363
Cites: 3
Cited by: 21
Related to: 9